Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [1][3] - The company will participate in two investor conferences in November 2025, showcasing its leadership and ongoing projects [2] Conference Participation - At the Guggenheim Annual Healthcare Innovation Conference on November 11, 2025, Paul Bolno, MD, MBA, President and CEO, will engage in an analyst-led fireside chat at 10:00 a.m. ET [2] - At the Jefferies London Healthcare Conference on November 20, 2025, Dr. Bolno will participate in an analyst-led fireside chat at 8:30 a.m. GMT / 3:30 a.m. ET and in the "Anti-Obesity Panel" at 9:00 a.m. GMT / 4:00 a.m. ET [2] Company Overview - Wave Life Sciences utilizes its RNA medicines platform, PRISM, which integrates various modalities and innovations in chemistry to address both rare and common disorders [3] - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - Wave Life Sciences is headquartered in Cambridge, MA, and is committed to advancing human health by overcoming disease burdens [3]

Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3] - The company will participate in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, with CEO Paul Bolno leading an analyst-led fireside chat [1] Company Overview - Wave Life Sciences utilizes its RNA medicines platform, PRISM, which integrates various modalities and chemistry innovations to address both rare and common disorders [3] - The company's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [3] - Wave Life Sciences is headquartered in Cambridge, MA, and aims to "Reimagine Possible" by alleviating the burden of disease on human potential [3]